Biocartis MSI Events

ECP 2018 - Sep 11th

ESMO 2018 - Oct 22nd

Idylla™ MSI Assay is for research use only and not for use in diagnostic procedures.

Direct Access

to personalized medicine


Fully Automated Molecular Testing


See how you can guide

the path her cancer takes


in-house cartridge

manufacturing line

A passionate team

driven to make a change


Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.


Idylla™, Biocartis’ fully automated, real-time Polymerase Chain Reaction (PCR) based molecular diagnostics system, is designed to offer physicians fast access to highly reliable clinical molecular diagnostic information, anywhere and anytime. Idylla™ detects and quantifies multiple DNA or RNA-based biomarkers in a wide variety of patient sample types. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the molecular diagnostics (MDx) market worldwide. Today, Biocartis has six oncology tests and two infectious disease tests in its offer.

Personalized Medicine

Personalized medicine is about every person’s unique genetic profile. Understanding and leveraging the molecular mechanisms underlying diseases, empowers doctors to shift away from the one-drug-fits-all paradigm and tailor a treatment to the genetic profile of their patient. Specific molecular diagnostics tests can help make treatments more effective, with better outcomes and as such, reduce healthcare costs.


Biocartis is a commercial-stage, small-cap molecular diagnostics (MDx) company listed on Euronext (ticker: BCART) since April 2015. We develop highly innovative diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform, launched in September 2014, is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.


Our main value driver is our menu of rapid, easy and highly accurate molecular diagnostics tests, focused on oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. In June 2016, we were active in over 50 countries and had close to 300 Idylla™ platforms installed at clients worldwide.